Loading...
ALXP
ALCOX
Market cap132mUSD
Oct 21, Last price  
3.34EUR
Name

Nicox

Chart & Performance

D1W1MN
ALXP:ALCOX chart
No data to show
P/E
P/S
647.36
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-19.05%
Revenues
257k
257,000
Net income
-21m
-20,881,000
CFO
Earnings
Jul 16, 2025

Profile

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
IPO date
Nov 02, 1999
Employees
28
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2023‑12
Income
Revenues
257
 
Cost of revenue
11,760
Unusual Expense (Income)
NOPBT
(11,503)
NOPBT Margin
Operating Taxes
(478)
Tax Rate
NOPAT
(11,025)
Net income
(20,881)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
25,153
Deferred revenue
Other long-term liabilities
713
Net debt
13,894
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
11,259
Long term investments
Excess cash
11,246
Stockholders' equity
(508,065)
Invested Capital
555,344
ROIC
ROCE
EV
Common stock shares outstanding
50,170
Price
Market cap
EV
EBITDA
(11,503)
EV/EBITDA
Interest
1,633
Interest/NOPBT